

Seracam® to be presented at Parathyroid Symposium 2023

Oral presentation on qualitative and quantitative capabilities and novel features of Seracam®

London, UK, 24 Feb 2023. Serac Imaging Systems Limited (“Serac Imaging Systems” or “the Company”), the medtech company developing a portable hybrid gamma/optical camera for medical imaging, today announces that an abstract titled ‘Seracam: A first look at a new portable gamma camera’ has been selected for oral presentation at the 5th Symposium on Parathyroid Fluorescence taking place 23-24 February 2023 in Geneva, Switzerland. Abstract 17 is available [here](#).

Dr Sarah Bugby, Lecturer in Physics, Loughborough University and scientific expert for the characterisation work being carried out on Seracam®, said:

“Seracam represents a step change in state-of-the-art for portable gamma camera systems. The ergonomics and set-up of this device make it well suited to small field of view procedures such as thyroid imaging, and the co-aligned gamma-optical hybrid imaging capability, which is unique to Seracam, could be especially helpful in radio guided surgical applications. More broadly, the compact size and portability of Seracam affords a significant new tool to complement existing imaging options and with the potential to expand the use of nuclear imaging and ultimately improve outcomes for patients.”

Oral Presentation of Abstract 17:

Seracam: A first look at a new portable gamma camera

Presenting author:	Andrew Farnworth, Loughborough University
Session:	9: Future Directions 2
Date and time:	24 February 2023 at 4.55pm

Mark Rosser, Chief Executive Officer of Serac Imaging Systems, added:

“We are delighted to be working with the University of Loughborough on the characterization work required for the development of Seracam ahead of clinical testing. We believe there is a great opportunity for Seracam to help physicians not only intraoperatively, but also at the point of care in a wide range of settings. This will enable better access to this important imaging modality for more patients, leading to more personalised and cost-effective treatments.”

About Seracam®

Seracam® is an innovative, compact and highly portable hybrid optical/gamma camera which is in development to bring the benefits of high-resolution molecular imaging to a patient’s bedside. This breakthrough technology will enable users to see the uptake of targeted tracers, labelled with minute amounts of radioactivity, to patients in a wide range of settings: an operating room, an intensive care unit, or a physician’s office. Currently the benefits of such imaging are largely confined to patients who can be referred to a hospital’s nuclear medicine department where the large, heavy and expensive conventional gamma cameras are sited in a fixed position in a dedicated room.

A further unique feature of Seracam®, is the combination of a gamma image overlaid with a co-aligned optical image of the same region of interest. This adds further information regarding the precise anatomical location

of the molecular imaging tracer and could be used to aid the discussion between the physician and patient regarding their condition and the optimal treatment path.

This presentation will outline the qualitative and quantitative capabilities of Seracam® and will highlight its potential to help in the assessment of thyroid disorders.

Clinical testing using Seracam® for a range of clinical applications, including thyroid imaging, is expected to commence in the second quarter of 2023.

About the Parathyroid Symposium

This is the fifth international symposium organised by the International Society of Innovative Technologies for Endocrine Surgery which gathers clinicians and scientists to examine new techniques which can help to increase the safety of thyroid and parathyroid surgeries.

www.parathyroid-symposium.ch

- ENDS -

For more information, please contact:

Serac Imaging Systems Ltd

www.seracimagingsystems.com

Mark Rosser, Chief Executive Officer

+44 (0)208 948 0000

info@seraclifesciences.com

Francetta Carr, Communications

+44 (0)7711 010 820

francettacarr@seraclifesciences.com

Notes to Editors

About Serac Imaging Systems

Serac Imaging Systems Ltd is the medtech company developing a portable hybrid gamma/optical camera for medical imaging. Our lead product is Seracam® which is in development to bring the benefits of high-resolution molecular imaging to a patient's bedside, instead of being confined for use in a hospital's nuclear medicine imaging department. A further unique feature of this technological approach is the overlay of a gamma image with an optical image of the same anatomical location under examination. Such portable and enhanced imaging technology has the potential to help clinicians make better, more informed and more timely treatment decisions. Seracam® is a UK and EU registered trademark.

Seracam® is for investigational use only and has not been cleared or approved by the FDA or UK and European regulatory authorities.

Serac Imaging Systems Ltd is a wholly owned subsidiary of Serac Life Sciences Limited.

For further details, please see www.seracimagingsystems.com

About molecular imaging

Molecular imaging is a type of medical imaging that provides unique insights into what is happening inside the body at the cellular and molecular level helping physicians to deliver personalised medicine by delivering the right treatment to the right patient at the right time. Unlike other medical imaging technologies such as x-rays, computed tomography (CT) and ultrasound (US) which provide structural images, molecular imaging allows physicians to see how cells, tissues and organs are functioning and to measure chemical and biological processes without having to resort to biopsy or surgery.